Resmetirom for NASH: MASESTRO-NASH Phase 3 Data in NEJM Precede PDUFA Date of 3-14-2024
Resmetirom vs placebo led to significantly greater proportion of adults reaching NASH resolution without increased fibrosis and with fibrosis improvement by ≥1 stage.
Migraine and Persistent Vasomotor Symptoms Linked to Higher Risk of CVD, Stroke in Analysis of CARDIA Study
Women with migraine and persistent VMS faced double the risk of CVD and triple the risk of stroke, reported researchers.
Global Obesity Rates Top One Billion, Quadrupling Among Youth from 1999-2022
Obesity rates in the US over the 3 decades rose from 11.5% to 21.7% among boys and from 11.6% to 19.4% among girls. US men ranked 10th highest for obesity in 2022.
Women with IBD at Risk for Reduced Fertility: Daily Dose
Your daily dose of the clinical news you may have missed.
Abrysvo Efficacy Sustained in Older Adults Through Second RSV Season
The bivalent vaccine demonstrated "durable efficacy" of more than 80% over 2 RSV seasons, according to Pfizer's report of topline findings from the RENOIR trial.
State of US Mental Health: Happiest Cities in 2024
Which city has the highest depression rate? Or the fewest work hours? Find the answers and more insights from a nationwide analysis, here.
Plasma Immunoassay for Alzheimer Disease Found Highly Accurate and is Commercially Available
The accuracy of the test in detecting Aβ and tau pathology underscores its potential to become an accessible and cost effective tool for Alzheimer diagnosis.
Marijuana Use Linked to Higher Risk of Myocardial Infarction, Stroke in New Study
The risk for cardiovascular outcomes increased with more frequent reported cannabis use per month, according to results from a large national study.
ACIP Recommends Monovalent COVID-19 Booster for Older Adults this Spring
COVID-19 hospitalizations have never fall below 6000/week, according to the ACIP; those aged 65+ have the highest inpatient rate, those aged 75+ have the highest mortality.
Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improves Lung Function, Asthma Control: Daily Dose
Semaglutide Shows Potential for Significant CVD Prevention in Analysis of Real-World Data
Analysis of heart registry data for SELECT trial-eligible adults (obesity, first MI, no diabetes) found an NNT of 49 and 5-year MACE incidence of 10.7%.
Salt Substitute Reduces HTN Risk among Older Adults with Normal BP: Daily Dose
8 Questions on the 2024 GOLD COPD Guidelines: A Quiz for Primary Care
Test your COPD IQ with these 8 questions on spirometry in COPD diagnosis, COPD exacerbations and treatment response, when to add ICS, and other topics for PCPs.
Viking Therapeutics Dual GIP/GLP-1 Mimetic Drives Weight Loss of Up to 14.7% in Phase 2 Findings
Viking's VENTURE trial met primary and all secondary endpoints, with GI-related TAEAs reported as mild/moderate and diminishing over the course of the 13-week study.
Atogepant Safe and Effective in Treatment-Resistant Episodic Migraine: ELEVATE Phase 3b Trial
Atogepant once daily reduced mean monthly headache days in adults for whom up to 4 classes of oral migraine preventives were ineffective.
Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers
AAAAI 2024. Needle phobia is just one of the barriers to not just using an epinephrine autoinjector but to carrying one at all, according to 2 sets of surveys findings.
Survodutide, Dual Glucagon/GLP-1 Mimetic, Improves MASH in 83% of Phase 2 Trial Participants
The statistically significant improvements in MASH with survodutide were seen without worsening fibrosis and included a relative reduction of steatosis of 30%.
First-Ever Long COVID Tissue Bank Launched at University of California San Francisco
"Viral reservoirs" in human tissue may preserve the SARS-CoV-2 virus, provoking an immune response that could drive long COVID-associated symptoms.
New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares
AAAAI 2024. In patients with treatment-resistant chronic spontaneous urticaria, neffy 1 mg and 2 mg resulted in improvement in itch, hives, urticaria, and erythema scores 5 minutes after dosing.
Impact of Regular Exercise on Hospitalization in Patients with COPD: Daily Dose
